Quantcast

Latest Pseudomonas infection Stories

Susceptibility Genes Can Be Revealed From Exome Sequencing Of Health Condition Extremes
2012-07-09 10:55:33

DNA from cystic fibrosis patients with and without chronic infections points to unsuspected mutation Comparing the DNA from patients at the best and worst extremes of a health condition can reveal genes for resistance and susceptibility. This approach discovered rare variations in the DCTN4 gene among cystic fibrosis patients most prone to early, chronic airway infections. The DCTN4 gene codes for dynactin 4. This protein is a component of a molecular motor that moves trouble-making...

2012-07-06 11:43:48

Researchers at Brigham and Women's Hospital (BWH) have discovered a new vaccine candidate for the bacterium Pseudomonas aeruginosa taking advantage of a new mechanism of immunity. The study was published online in the American Journal of Respiratory and Critical Care Medicine on June 21, 2012. Pseudomonas aeruginosa is a leading cause of hospital-acquired infections, particularly in patients on respirators, where it can cause so-called ventilator-associated pneumonia, which carries a...

2012-05-23 20:09:40

Patients with chronic obstructive pulmonary disease (COPD) who become infected with the bacterium Pseudomonas aerguinosa are more likely to have worse clinical outcomes and experience more hospitalizations during the course of their disease than COPD patients who are not infected, according to researchers from Buffalo, N.Y. The study will be presented at the ATS 2012 International Conference in San Francisco. Bacterial bronchial infection plays a key role in the course of COPD, causing...

2011-06-10 10:00:00

MONMOUTH JUNCTION, N.J., June 10, 2011 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced positive data through six treatment cycles (72 weeks total duration) of its Phase 2 clinical trial program for ARIKACE® (liposomal amikacin for inhalation) in cystic fibrosis (CF) patients with Pseudomonas lung infections. The data were presented at the 34th European Cystic Fibrosis Conference in Hamburg, Germany, by Predrag Minic,...

2011-04-01 01:18:00

VIENNA, April 1, 2011 /PRNewswire/ -- Today Intercell AG (VSE: ICLL) announced that it has agreed with Novartis to advance Intercell's investigational Pseudomonas aeruginosa vaccine into a confirmatory clinical efficacy trial in ventilated ICU (Intensive Care Unit) patients. The planned double blind study is powered to show a clinically meaningful and statistically significant reduction in overall mortality between the vaccine and control group and envisages enrolling about 800 subjects....

f9aafb10d73bc329282696ab3af380b01
2011-02-22 09:40:40

The bacterium, called Pseudomonas aeruginosa, is the most common cause of persistent and fatal lung infections in cystic fibrosis patients. Scientists at Liverpool identified a particularly virulent strain of the bacteria that is transmissible between patients. The Liverpool Epidemic Strain (LES), referred to as a cystic fibrosis 'superbug', can cause aggressive infection and results in progressive lung decline. The team from the University's Institute of Infection and Global Health took...

2010-01-04 14:01:55

New research in the Journal of Leukocyte Biology shows that glycyrrhizin extracted from licorice root helps the body defend against Pseudomonas aeruginosa infection As it turns out, children were not the only ones with visions of sugar plums dancing in their heads over this past holiday season. In a new research report published in the January 2010 issue of the Journal of Leukocyte Biology (http://www.jleukbio.org), a team of scientists from the University of Texas Medical Branch and Shriners...

2009-06-25 08:45:00

Company Also Receives Patent Covering ARIKACE for Once-Daily Treatment of Pseudomonas Lung Infections MONMOUTH JUNCTION, N.J., June 25 /PRNewswire/ -- Cystic Fibrosis Foundation Therapeutics Inc., the nonprofit affiliate of the Cystic Fibrosis Foundation, has provided a $2.2 million award to Transave Inc., for the continued development of ARIKACE(TM) (liposomal amikacin for inhalation), an antibiotic that aims to treat Pseudomonas lung infections in cystic fibrosis (CF) and non-CF...

2009-04-30 10:50:00

ZURICH, Switzerland, April 30 /PRNewswire/ -- An innovative treatment for infections of the respiratory tract in cystic fibrosis patients has received orphan drug designation in the US. Axentis Pharma of Zurich, Switzerland announced today that this sought-after designation has been granted to its product candidate Fluidosomes-tobramycin, a therapeutic that will soon be tested in Phase II clinical trials. The company has now been granted orphan drug designation for this candidate in both...


Word of the Day
holluschickie
  • A 'bachelor seal'; a young male seal which is prevented from mating by its herd's older males (mated bulls defending their territory).
This comes from the Russian word for 'bachelors.'
Related